MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by LIMBIRD, L. E.
Right arrow Articles by LEFKOWITZ, R. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by LIMBIRD, L. E.
Right arrow Articles by LEFKOWITZ, R. J.

Molecular Pharmacology, Vol 12, 559-567, Copyright © 1976 by the American Society for Pharmacology and Experimental Therapeutics

Adenylate Cyclase-Coupled Beta Adrenergic Receptors: Effect of Membrane Lipid-Perturbing Agents on Receptor Binding and Enzyme Stimulation by Catecholamines

LEE E. LIMBIRD 1 and ROBERT J. LEFKOWITZ 1

1 Departments of Medicine and Biochemistry, Duke University Medical Center, Durham, North Carolina 27710

Binding of (-)-[3H]dihydroalprenolol, a potent competitive beta adrenergic antagonist, to sites in frog erythrocyte membranes has previously been demonstrated to possess the essential properties expected of binding to adenylate cyclase-coupled beta adrenergic receptors. The present studies were designed to test the effects of a variety of membrane lipid-perturbing agents on both beta adrenergic receptor binding and catecholamine-responsive adenylate cyclase in frog erythrocyte membranes. Digestion of membranes with phospholipases A, C, and D causes a dose-dependent decline in receptor binding capacity without altering receptor affinity. Amphotericin B, a nondegradative membrane lipid perturbant, also causes a dose-dependent decrease in (-)-[3H]dihydroalprenolol binding. Decrements in catecholamine-stimulated adenylate cyclase activity caused by these agents are always greater than decreases in basal and fluoride-sensitive enzyme activities. Decreases in (-)-[3H]dihydroalprenolol binding parallel the disproportionate reduction in catecholamine responsiveness of adenylate cyclase. By contrast, the polyene antibiotic Filipin appears to "uncouple" receptor binding and enzyme activation, since a marked reduction in isoproterenol-stimulated adenylate cyclase is not accompanied by a decrease in specific (-)-[3H]dihydroalprenolol binding.

Note:
ACKNOWLEDGMENTS The electron microscopic studies in consultation were performed by Dr. J. R. Sommer, Director, Veterans Administration EM Laboratory, Veterans Administration Hospital, Durham, N. C. The authors thank Dr. Mary Ellen Switzer for fibrinogen degradation studies and Dr. Patrick McKee for helpful discussion. The authors also acknowledge Mr. Michael Coverstone for technical assistance.

Submitted on September 2, 1975




This article has been cited by other articles:


Home page
 J. Biol. Chem.Home page
H. Park, Y.-M. Go, P. L. St. John, M. C. Maland, M. P. Lisanti, D. R. Abrahamson, and H. Jo
Plasma Membrane Cholesterol Is a Key Molecule in Shear Stress-dependent Activation of Extracellular Signal-regulated Kinase
J. Biol. Chem., November 27, 1998; 273(48): 32304 - 32311.
[Abstract] [Full Text] [PDF]

Home page
 HypertensionHome page
N. D. Woo and P. K. Ganguly
Neuropeptide Y Prevents Agonist-Stimulated Increases in Contractility
Hypertension, September 1, 1995; 26(3): 480 - 484.
[Abstract] [Full Text]

Home page
 ScienceHome page
T Akera
Membrane adenosinetriphosphatase: a digitalis receptor?
Science, November 11, 1977; 198(4317): 569 - 574.
[Abstract] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1976 by the American Society for Pharmacology and Experimental Therapeutics